The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Recent updates and emerging therapies in essential thrombocythemia
In this video, Olatoyosi Odenike, MD, University of Chicago, Chicago, IL, comments on promising emerging therapies for the management of essential thrombocythemia (ET), including pegylated interferon agents and immunotherapeutic approaches targeting mutant calreticulin (CALR). Prof. Odenike highlights that this is an exciting time in the field of ET, and she looks forward to further data and advancements in this disease area. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For ET, again, this is very exciting times. I can’t remember a time in recent memory where we’ve had this sort of excitement around new approaches in ET. A top class of agents that is now really kind of finding itself into the mainstream in the management of patients with ET would be pegylated interferon agents. Specifically, ropegylated interferon has been investigated in a randomized setting in ET compared with anagrelide in individuals who have not responded to hydroxyurea, which is one of the standard ways of managing high-risk ET...
For ET, again, this is very exciting times. I can’t remember a time in recent memory where we’ve had this sort of excitement around new approaches in ET. A top class of agents that is now really kind of finding itself into the mainstream in the management of patients with ET would be pegylated interferon agents. Specifically, ropegylated interferon has been investigated in a randomized setting in ET compared with anagrelide in individuals who have not responded to hydroxyurea, which is one of the standard ways of managing high-risk ET. And ropeg far outperformed anagrelide in that setting. So I’m really excited to be able to have this sort of incorporated into ways in which we think about approaching ET that’s perhaps a bit more challenging to treat. And then finally, I already alluded to the calreticulin monoclonal antibody approaches, bispecific therapy engaging approaches, and other immunotherapy agents targeted to mutant calreticulin. I can’t wait to see how all of that pans out.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
